Rafey, M. F.
Fang, C. E. H.
Ioana, I.
Griffin, H.
Hynes, M.
O’Brien, T.
McAnena, O.
O’Shea, P.
Collins, C.
Davenport, C.
Finucane, F. M.
Article History
Received: 20 January 2020
Accepted: 17 September 2020
First Online: 1 October 2020
Competing interests
: M.F. Rafey, C.E.H. Fang, I. Ioana, H. Griffin, M. Hynes, O. McAnena, P. O’Shea and C. Collins declare that they have no competing interests. T. O’Brien has served on advisory boards for MSD and Novo Nordisk. C. Davenport has received honoraria and served on advisory boards for Novo Nordisk. F.M. Finucane have received honoraria, travel grants and have served on advisory boards for Novo Nordisk, Eli Lilly, Ethicon, Pfizer Inc., Sanofi-Aventis, Astra Zeneca, Merck-Serono, Boehringer Ingelheim, Janssen and Novartis up until 2017 but none since then.